GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines.
Comparative genomic hybridization (CGH) analyses have detected gains of copy number on 13q, especially at 13q31-q32, in cell lines and primary cases of various types of lymphoma. Since amplification of chromosomal DNA is one of the mechanisms that can activate tumor-associated genes, and because 13q amplification had been reported in various other types of tumors as well, we attempted to define by fluorescence in situ hybridization (FISH) a common region at 13q31-q32 in which to explore genes that might be targets for the amplification events. Although the commonly amplified region we defined was relatively large (approximately 4 Mb), only one true gene, GPC5, was found there. GPC5 was over-expressed in lymphoma cell lines that had shown amplification, in comparison with those that had not. Our findings suggest that GPC5 is a likely target for amplification, and that over-expression of this gene may contribute to development and/or progression of lymphomas and other tumors.
Yu
Wei
W
Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
Inoue
Jun
J
Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.|Theranostics Research Center (TRC), Otsuka Pharmaceutical Co., 463-10 Kagasuno Kawauchi-cho, Tokushima 771-0192, Japan.
Imoto
Issei
I
Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.|Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), 4-1-8 Honmachi, Kawaguchi 332-0012, Japan.
Matsuo
Yoshinobu
Y
Fujisaki Cell Center, Hayashibara Biochemical Laboratories, 675-1 Fujisaki, Okayama 702-8006, Japan.
Karpas
Abraham
A
Department of Hematology, University of Cambridge Clinical School, MRC Centre, Hills Road, Cambridge, CB2 2QH, United Kingdom.
Inazawa
Johji
J
Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. johinaz.cgen@mri.tmd.ac.jp.|Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), 4-1-8 Honmachi, Kawaguchi 332-0012, Japan. johinaz.cgen@mri.tmd.ac.jp.
D045744:Cell Line, Tumor; D022202:Chromosomes, Artificial, Bacterial / Q000235:genetics; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics*; D004273:DNA, Neoplasm; D016326:Extracellular Matrix Proteins; D005784:Gene Amplification; D018628:Gene Dosage; D053673:Glypicans; D019812:Heparan Sulfate Proteoglycans / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008223:Lymphoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis
D004273:DNA, Neoplasm; D016326:Extracellular Matrix Proteins; C106228:GPC5 protein, human; D053673:Glypicans; D019812:Heparan Sulfate Proteoglycans; D012333:RNA, Messenger